Clinical Trial Update: Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy, safety, tolerability, and pharmacokinetics of nilotinib in pulmonary arterial hypertension was terminated with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: TERMINATED | Results posted: 2014-02-27